Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Brightseed Inc. has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, STEADMAN, DAVID J, who is the busiest examiner for the company with 1 pending action. The portfolio's pending activity is restricted to 1 distinct art unit.
For the practitioner, this setup implies that the prosecution of the 1 pending office action is a high focus task with no room for error. Since STEADMAN, DAVID J is the only examiner involved, his specific interpretation of Biotechnology & Pharmaceuticals guidelines will be the deciding factor. The presence in only 1 distinct art unit suggests that Brightseed Inc. is targeting a very specific niche within its technology area. Practitioners should prepare for a highly focused examination process where the history of STEADMAN, DAVID J in this 1 art unit is the most critical piece of intelligence. Without other pending actions to provide variety, the strategy must be perfectly aligned with this 1 examiner's expectations.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEADMAN, DAVID J | 1 | 57.7% | +29.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17726926 | RECOMBINANT CELL, EXTRACT, CONSUMABLE PRODUCT AND METHOD FOR PRODUCTION OF BIOACTIVE PLANT METABOLITE | STEADMAN, DAVID J | — |
| Art Unit | Apps |
|---|---|
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17726926 | RECOMBINANT CELL, EXTRACT, CONSUMABLE PRODUCT AND METHOD FOR PRODUCTION OF BIOACTIVE PLANT METABOLITE | STEADMAN, DAVID J | 1656 | §103 | Final Rejection | — | Pending | Apr 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBrightseed Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
David J Steadman has the most, with 1 of Brightseed Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
